CHELSEA PANTALONE: Open Payments
NPI 1649915489 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,789 in 79 payments from 16 companies in 2025. Trend: 2023 $714 · 2024 $890 · 2025 $1,789
Food & beverage: $1,789
| Company | Payments | Amount |
|---|---|---|
| Lundbeck LLC | 18 | $265 |
| Amgen Inc. | 3 | $255 |
| Teva Pharmaceuticals USA, Inc. | 15 | $232 |
| ABBVIE INC. | 4 | $193 |
| Alkermes, Inc. | 8 | $149 |
| Otsuka America Pharmaceutical, Inc. | 7 | $145 |
| Vanda Pharmaceuticals Inc. | 4 | $115 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $97 |
| Neurocrine BioSciences, Inc. | 3 | $76 |
| Gilead Sciences, Inc. | 3 | $67 |
Products named: REPATHA, REXULTI, MAVYRET, ARISTADA, UZEDY, ABILIFY ASIMTUFII, AUSTEDO XR, CAPLYTA.
Industry payments across MD — which companies pay providers there.
